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Oral cancers represent 4% of all cancers in the West, whereas, in
developing countries including India, it accounts for up to 45% of
all cancers (Johnson and Warnakulasuriya, 1993). Globally, oral
cancer ranks as the sixth most common cancer, with evidence of an
increase in incidence rate and mortality due to this cancer in recent
years, particularly in young adults in Central Europe (Notani,
2000). The major aetiologic factors in the development of oral
cancer constitute tobacco chewing/smoking and alcohol con-
sumption (Choi and Kahyo, 1991; Johnson and Warnakulasuriya,
1993; Notani, 2000). Recently high-risk human papillomaviruses
(HPVs), have been implicated as important aetiologic agents,
particularly in the oral cancers with no tobacco or alcohol associa-
tions (D’Costa et al, 1998; Gillison et al, 2000). In spite of
advances in surgery, radiotherapy and chemotherapy, the 5-year
survival rates in oral cancer are among the lowest (Johnson, 1991).
In India, greater than 70% of oral cancers are observed in
advanced stages III/IV, by the clinicians. Unlike in the West, most
of the oral cancers seen in India, are preceded by distinct prema-
lignant lesions such as leukoplakia and submucous fibrosis (Gupta
et al, 1989). Further, although a majority of oral cancers occur in
individuals with tobacco/alcohol habits, only a small proportion of
tobacco habits develop oral cancer. Hence, identification of high-
risk premalignant lesions with increased susceptibility to oral
cancer and consequent aggressive follow up for change of habit
and early detection, may help in down staging of the cancer and
better prognosis. A genetic marker to indicate increased suscept-
ibility would be useful in this scenario. 
Studies from our laboratory on molecular alterations including
genomic instability using microsatellite markers and inactivation
of p53 tumour suppressor gene in oral cancers and oral lesions
have been reported (Saranath et al, 1999; Mahale and Saranath,
2000). The p53 gene inactivation via mutations, overexpression,
deletions and binding to viral proteins has been demonstrated in
oral cancers and oral lesions (Raybaud-Diogene et al, 1996;
Saranath et al, 1997, 1999). Recently, a common polymorphism in
p53 gene at exon 4 codon 72, encoding for either a proline (CCC)
or arginine (CGC) amino acid, has been implicated in suscept-
ibility to certain cancers, with a reported increased prevalence of
Arg/Arg genotype in cervical cancer and Pro/Pro genotype in lung
cancer (Kawajiri et al, 1993; Jin et al, 1995; Murata et al, 1996;
Storey et al, 1998). On the other hand, no association between
either Pro/Pro or Arg/Arg genotypes and increased susceptibility
has been reported for cancers of breast, bladder, colorectal and
head and neck (H & N) (Kawajiri et al, 1993; Hamel et al, 2000). 
In the present study we analysed p53 genotypes in oral cancer
patients, to examine the genotypic distribution and association
with susceptibility to the cancer. The p53 polymorphism was
studied in constitutional peripheral blood cell (PBC) DNA, both
from the cancer patients and from normal controls. This was
essential, as tumour associated lesions in the p53 polymorphic
loci, may introduce a bias in genotypic analysis. Further, in our
previous studies examining loss of heterozygosity (LOH) in oral
cancer tissues, using the same p53 polymorphism in a PCR-
restriction fragment length polymorphism (PCR-RFLP) assay,
tumour-associated LOH was observed in 20% of the samples
(Saranath et al, 1997). The earlier study used primers to amplify
exon 4 codon 72, with the PCR product digested by Accll enzyme,
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distribution was not analysed in the study. 
MATERIALS AND METHODS 
Study population 
The samples constituted 72 oral cancer patients, with histopatho-
logically confirmed squamous cell carcinoma (SCC) of the oral
cavity. Primary site of tumours included buccal mucosa – 39 cases,
alveolus – 22 cases, tongue – 10 cases and lip – 1 case. 20 ml
peripheral blood and matching primary tumours were collected
from all the patients at the time of surgery, from Tata Memorial
Hospital, Mumbai, India. Informed consent was obtained from 
the patients. Tumour tissues and the leucocytes separated from the
peripheral blood, were stored at –70˚C until further use. 
Peripheral blood cells from 153 normal healthy volunteers were
collected to compare the p53 codon 72 polymorphism in cancer
patients with that in healthy individuals of Indian ethnicity. 
DNA extraction 
DNA was extracted from the PBCs and oral tumour tissue samples
using standard procedure, involving SDS/Proteinase K, ribo-
nuclease A, phenol-chloroform extraction of proteins and ethanol
precipitation of DNA, as detailed earlier (Saranath et al, 1989). 
PCR 
Analysis of the p53 genotype at exon 4 codon 72, was performed
as described by Storey et al (1998), with minor modifications.
Proline and arginine specific sequences were used for the in vitro
amplification. The primer sequences were as follows: Pro specific
primers: Sense primer (codons 66–72): 5¢ GCC AGA GGC TGC
TCC CCC 3¢, Antisense primer (Codons 120–126): 5¢ CGT GCA
AGT CAC AGA CTT 3¢; Arg specific primers: Sense primer
(Codons 33–38): 5¢ TCC CCC TTG CCG TCC CAA 3¢, Antisense
primer (Codons 72–78): 5¢ CTG GTG CAG GGG CCA CGC 3¢.
Briefly, the reaction mixture contained 100 ng of sample DNA, in
a total reaction volume of 15 ml constituting 10 mM Tris buffer pH
8.4, 50 mM KCl, 1.5 mM MgCl2; 200 mM each of dATP, dCTP,
dGTP, and dTTP; 100 ng each Pro sense and antisense primers and
a duplicate tube with Arg sense and antisense primers; 0.01%
bovine serum albumin and 0.125 units of Taq polymerase (Gibco-
BRL, USA). The DNA was subjected to 35 cycles of PCR with
denaturation at 94˚C for 30 s, annealing at 59˚C for 30 s, and
extension at 72˚C for 30 s, followed by a final extension at 72˚C
for 5 min. 
The PCR products were electrophoresed on 11% denaturing
polyacryamide gel, at 50˚C, using 25 mA current for 2 h. After
electrophoresis the gel was fixed in 10% acetic acid: 45%
methanol for 30 min, and subjected to two washes of 50% ethanol.
The p53 alleles were visualized by silver staining. Briefly, the gel
was treated with 3% nitric acid, rinsed with distilled water and
treated with 0.2% silver nitrate in presence of 0.1% formaldehyde.
The bands were visualized by treating the gel with 3% sodium
carbonate containing 0.1% formaldehyde, until a strong brown
colour was apparent. The reaction was arrested by immersing the
gel in 2% glacial acetic acid. 
Statistical analysis 
Chi-square test was performed to compare p53 genotype distribu-
tion in the patient and control groups. The Hardy–Weinberg
equilibrium was tested by a goodness-of-fit c2 test to compare 
the observed genotypic frequencies in normal individuals to the
expected genotypic frequencies, calculated from the observed
allelic frequencies. 
RESULTS 
p53 Pro and Arg genotype frequencies 
Polymerase chain reaction amplification using p53 Pro specific
primers, amplified a 177 bp fragment; whereas p53 Arg allele de-
monstrated a 141 bp fragment. A representative polyacrylamide
gel with samples showing the different alleles, is demonstrated in
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Table 1 Frequency of *Pro/Arg polymorphism at p53 gene loci in oral cancer cases and controls and LOH observed in oral cancers 
Samples p53 Genotypes
No. of cases with LOH/No. of  
Pro/Pro n (freq) Arg/Arg n (freq) Pro/Arg n (freq)  heterozygous cases (Pro/Arg)
Oral cancers (n = 72) 14  6  52  8/52 (15)
(0.19) (0.08) (0.72)
Healthy controls (n = 153) 31  22  100 
(0.20) (0.14) (0.65) 
*The constitutive presence of Pro/Arg genotypes in the PBC is given. LOH = loss of heterozygosity. 
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Figure 1 Polyacrylamide gel electrophoresis of p53 codon 72 alleles in
matched normal (N) and oral tumour (T). Pro and Arg specific primers
amplified 177 bp and 141 bp products respectively. Pro/Pro homozygous
genotype showed 177 bp fragment whereas Arg/Arg homozygous genotype
showed 141 bp fragment. Pro/Arg heterozygous genotype demonstrated
presence of both the fragments, 177 bp and 141 bp. Negative control (Neg.
control) does not contain DNA. Sample 62 shows loss of Arg allele in the
tumour tissue, on comparison with corresponding peripheral blood cell DNA the figure (Figure 1). Thus, homozygous Pro alleles demonstrated
a 177 bp fragment, and homozygous Arg alleles showed 141 bp
fragment; whereas p53 Pro/Arg heterozygous alleles showed pres-
ence of both the fragments, 177 bp and 141 bp (Figure 1). The
Pro/Arg polymorphic frequency distribution in healthy controls
and oral cancer patients is shown in Table 1. There was no signific-
ant difference in the distribution of the 3 genotypes between the
oral cancer patient group and normal healthy controls (c2 = 1.77;
df = 2; 0.3 < P < 0.5). 
Loss of heterozygosity was studied by comparison of the p53
genotype in the PBC with the observed genotype in correspond-
ing tumour tissue. The loss was detectable as complete loss of an
allelic fragment and represented as LOH in the heterozygous
samples. LOH was indicated as loss of either the Pro allele or 
Arg allele. We observed tumour-associated loss in 8 of 52 (15%)
heterozygous oral cancer patients as shown in Table 1 (Figure 1). 
Statistical analysis 
There was no statistically significant difference in the frequencies
of the 3 genotypes Pro/Pro, Arg/Arg and Pro/Arg, between healthy
controls and oral cancer patients (c2 = 1.77; df = 2; 0.3 < P < 0.5).
However, a significant deviation from the Hardy–Weinberg 
equilibrium was observed in normal controls (c2 = 14.775, df = 1,
P < 0.001) as well as in oral cancer patients (c2 = 19.489, 
df = 1, P < 0.001). 
DISCUSSION 
Several studies have examined frequency of the p53 genotypes,
Pro/Pro and Arg/Arg in human cancers, such as lung, colorectal,
breast, stomach, bladder, H & N and cervical cancer to analyse
association of this polymorphism with cancer susceptibility
(Kawajiri et al, 1993; Jin et al, 1995; Storey et al, 1998; Hamel 
et al, 2000). Studies on bladder, breast and colorectal cancer
showed no association between p53 polymorphism and the malig-
nancies (Kawajiri et al, 1993; Sjalander et al, 1995). However,
presence of Arg/Arg genotype has been associated with increased
susceptibility to cervical cancer and Pro/Pro genotype with lung
cancers (Kawajiri et al, 1993; Jin et al, 1995; Murata et al, 1996;
Storey et al, 1998). A single study on H & N cancer analysing 163
patients from Canada, demonstrated no over-representation of
Arg/Arg genotype in H & N SCC cases compared to controls, over
different tobacco exposure strata (Hamel et al, 2000). 
In the present study, we examined p53 exon 4 codon 72 poly-
morphism in normal healthy individuals and oral cancer patients,
both groups representing ethnically similar backgrounds. PBC
DNA was used in both the groups for the analysis, to represent the
constitutional genotypes, as tumour-associated lesion in the p53
gene are common and may introduce a bias in the genotypic fre-
quencies (Saranath et al, 1999). In our studies, the genotypic distri-
bution was similar in the normal individuals and the oral cancer
patients (c2 = 1.77, df = 2, 0.3 < P < 0.5), although deviation from
Hardy–Weinberg equilibrium was noted in both the control and the
oral cancer population. A deviation from Hardy–Weinberg equilib-
rium among African-American sample controls with respect to the
p53 Pro/Arg genotype has been reported earlier, by Jin et al (1995).
The authors attributed the deviation to a relative excess of heterozy-
gotes. In this study, besides the excess of heterozygotes in both the
controls and the oral cancer patients, the cases as well as controls
consisted of non-communicating stratas i.e. Hindus, Muslims,
Christians and their subcastes, which generally do not intermarry.
Thus, even though Hardy–Weinberg equilibrium holds within a
strata, it may not hold in a mixed sample such as the present data.
Hamel et al (2000), have indicated the importance of using controls
derived from the same population as the cases and adequate sizing
of the control group, of crucial importance to the validity of geno-
typing studies. In the current study, the control and the patient
group contained ethnically similar proportion of different castes
and subcastes of Indians. Our results in oral cancer showed no over-
representation of Arg/Arg genotype in oral cancer patients,
analysed in PBC DNA representing the constitutive presence of
genotypes. Thus, p53 codon 72 polymorphism was not associated
with susceptibility to oral cancer. 
In the oral cancer group, we also examined tumour-associated
alterations in the p53 gene, by examining corresponding PBC and
tumour tissue DNA from individual patients. This enabled us to
determine LOH in cancer patients, as allelic deletion is one of
the mechanisms of p53 inactivation. Loss of heterozygosity was
observed in the current study in 15% of oral cancer tissues. The
results were comparable to our earlier study analysing LOH using
PCR-RFLP analysis, with 20% of the oral cancer patient tissues
showing LOH of p53 exon 4 codon 72 (Saranath et al, 1997).
Largey and co-workers (1993) have demonstrated relatively higher
LOH of 71% (10/14) in smoking tobacco-associated oral cancers
from USA, albeit the sample size of 14 informative cases was
rather small. Differences in the molecular profile between Indian
chewing tobacco-associated oral cancers and smoking-related
cancers from the West have been reported earlier (Saranath et al,
1993, 1999; Raybaud-Diogene et al, 1996; Saranath, 2000). 
In the Indian oral cancer patients, the prevalence of chew-
ing tobacco is high, with the attributable risk of tobacco varying
from 61% to 70% for the cancer (Notani, 2000). However, not all
tobacco habitues develop oral cancer. Genetic susceptibility may
give us a clue as to the tobacco habitues who will develop oral
cancer with increased possibility. Hence, such studies at specific
loci suspected to increase genetic susceptibility to human cancers
are necessary. In the current study we observed a difference in the
p53 genotypic distribution from reported literature, and an equidis-
tribution of the genotypes in control and oral cancer patients. Thus,
p53 genotype was not associated with increased susceptibility to
oral cancer. 
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